San Nuo Bio: The appeal against the overseas related patent infringement was rejected, maintaining the previous preliminary injunction ruling.

LightningPacketLoss · 2026-04-03T16:36:25+00:00

Sino Biotech announced that the European Unified Patent Court dismissed its appeal against A Menarini Diagnostics, upholding the temporary ban on GlucoMen iCan CGM. This ruling is a precautionary measure and does not constitute a final judgment. The involved amount is between €200,000 and €400,000. The company will actively respond to the case, and the ultimate impact remains uncertain.

LightningPacketLoss

2026-04-03 16:36:25

Abstract generation in progress

April 1, Nuonuo Biotech announced that the Court of Appeal of the Unified Patent Court (UPC) in Europe dismissed the appeal requests filed by the company and A Menarini Diagnostics S.r.l., and upheld the interlocutory injunction ruling made by the Hague UPC division regarding the GlucoMen iCan CGM product.

The announcement stated that the Unified Patent Court decision covered by this announcement is the outcome of the review of an appeal against an “interlocutory injunction (Preliminary Injunction, PI),” and is not a final judgment on the issues in the case. The interlocutory injunction is a precautionary measure taken before the final hearing of the case and does not represent the court’s final determination on the infringement facts or the validity of the patent. The estimated amount involved in this ruling is €200,000–€400,000.

The company is actively preparing for the case’s plaintiff and defense proceedings and related response work. As the main trial has not yet opened, the outcome of the final judgment remains uncertain, and the specific impact on the company’s subsequent-period profits is also uncertain.

( Nuonuo Biotech announcement )

(Edited by: Yang Yan, Lin Chen)

Keywords:

                                                            Medical

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes